|View printer-friendly version|
|Array BioPharma to Present Clinical Data at the European League Against Rheumatism (EULAR) Annual Meeting and the 8th World Congress on Inflammation|
BOULDER, Colo.--(BUSINESS WIRE)--May 30, 2007--Array BioPharma Inc. (Nasdaq: ARRY) today announced that its scientific team will present clinical data on the MEK inhibitor, ARRY-162 and p38 inhibitor, ARRY-797, at the Annual European Congress of Rheumatology (EULAR) in Barcelona, Spain and the International Association of Inflammation Societies' (IAIS) 8th World Congress on Inflammation in Copenhagen, Denmark.
Event: European League Against Rheumatism (EULAR) Annual Meeting Date: Saturday, June 16, 2007 Location: CCIB -Barcelona International Convention Center, Spain Title: ARRY-162, a selective, potent MEK 1 / 2 inhibitor, significantly reduces ex vivo IL-1(beta) and TNF(alpha) production in normal human subjects Presenter: Kevin Koch, Ph.D, President and Chief Scientific Officer Title: ARRY-797, a selective, potent inhibitor of p38, promotes disease normalization in animal models of rheumatoid arthritis and significantly reduces ex vivo IL-1(beta), PGE2 and TNF(alpha) production in normal human subjects Presenter: Patrice Lee, Ph.D., Director, Pharmacology and Toxicology Event: IAIS' 8th World Congress on Inflammation Location: Bella Center, Copenhagen, Denmark Title: The effects of MEK Inhibitors in Cancer and Inflammation Presenter: Kevin Koch, Ph.D, President and Chief Scientific Officer Date: Sunday, June 17, 2007 at 10:30 a.m. Title: ARRY-797, a selective, potent inhibitor of p38 active in animal models of rheumatoid arthritis, inhibits ex vivo IL-1, PGE2 and TNF production in normal human subjects Presenter: Kevin Koch, Ph.D, President and Chief Scientific Officer Date: Monday, June 18, 2007 at 5:15 pm Title: ARRY-162, a selective, potent MEK 1 / 2 inhibitor, significantly reduces ex vivo IL-1 and TNF production in normal human subjects Presenter: James Winkler, Ph.D., Senior Director, Discovery Biology Date: Wednesday, June 20, 2007 at 11:15 am Title: Soft, topical immunosuppressants derived from Cyclosporin A for the treatment of atopic dermatitis Presenter: Laurence Burgess, Ph.D., Senior Director, Medicinal Chemistry and Lead Optimization Date: Tuesday, June 19, 2007 at 5:45 pm
All posters will be available as PDFs after they are presented on Array's website: www.arraybiopharma.com.
About Inflammatory Disease
Inflammation is a natural biologic response to injury or infectious attack to the human body. Unregulated inflammation results in a broad range of conditions, most of which are classified by the tissue or organ where the inflammation occurs. These conditions include rheumatoid arthritis in the joint, psoriasis in the skin, COPD in the lung, fibrotic disease in the liver and kidney, Crohn's disease in the intestine, CHF and arteriosclerosis in the arteries. Currently, some of the most effective treatments for these diseases are injected protein therapeutics, which have significant cost and patient compliance issues. Injectable protein therapeutics currently on the market, such as Enbrel, Remicade, Humira and Kineret, bind to and/or modulate the activity of the inflammatory cytokines TNF or IL-1. There remains a significant unmet medical need for improved therapies to treat COPD, asthma, fibrosis and cardiovascular diseases. We believe there is a significant opportunity to create orally active drugs to treat many of these often-chronic diseases. We are developing drugs that modulate important biological targets in key intracellular pathways that control inflammation, potentially providing the ability to treat multiple diseases with a single oral agent. According to EvaluatePharma, the worldwide market for injectable targeted therapies for rheumatoid arthritis alone is expected to grow from $10 billion in 2006 to $18 billion in 2012. Additionally, with the safety concerns over the class of pain medications known as COX-2 inhibitors, new markets for replacement drugs to treat pain associated with rheumatoid arthritis and osteoarthritis are likely to develop.
About ARRY-162 / MEK for Inflammation
MEK is an enzyme that regulates the biosynthesis of the inflammatory cytokines TNF, IL-6 and IL-1. Array scientists have discovered potent MEK inhibitors that interfere with these biosynthetic processes. We have previously advanced one MEK inhibitor, ARRY-886, into clinical development for the treatment of cancer. Given our experience with the safety profile of MEK inhibitors, we believe inhibition of MEK will have broad applications in diseases driven by IL-1 and TNF. ARRY-162, an orally active MEK inhibitor, has shown significant efficacy and is well tolerated in preclinical models of human arthritis and other inflammatory diseases. We initiated Phase 1 clinical testing in normal volunteers in April 2006.
About ARRY-797 / p38 for Inflammation and Cancer
p38 is an enzyme that regulates the production of numerous pro-inflammatory cytokines, in particular, TNF, IL-6 and IL-1. Additionally, several cancers have show up-regulation of TNF and IL-6, including prostate, ovarian and multiple myeloma; p38 may be involved as part of a resistance mechanism. ARRY-797, an orally active p38 inhibitor, has demonstrated significant efficacy and is well tolerated in preclinical models of human arthritis and certain cytokine-driven cancers. We initiated Phase 1 clinical testing in 2006.
About Array BioPharma:
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. Our proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.
Array BioPharma Forward-Looking Statement:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Array's clinical development plans and advancing Array's drug development pipeline. These statements involve significant risks and uncertainties, including those discussed in our annual report filed on form 10-K for the year ended June 30, 2006, our quarterly report on Form 10-Q for the quarter ended March 31, 2007, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to continue to fund and successfully progress internal research efforts and to create effective, commercially viable drugs, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities, our ability to out-license our proprietary candidates on favorable terms, risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates, the ability of our collaborators and of Array to meet objectives tied to milestones and royalties, and our ability to attract and retain experienced scientists and management. We are providing this information as of May 30, 2007. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.
CONTACT: Array BioPharma Inc.